Verge Genomics’ Post

Betting on BET: The First Selective Brd4 BD2 Inhibitor for Inflammatory/Autoimmune Disease with Georg Duenstl from DeepCure. We designed the first Brd4-BD2-selective inhibitor, which we are developing for inflammatory diseases. BET was an oncology therapeutic target until efficacy and tox concerns became evident. Pan-BD2 BET inhibitors have shown in vivo anti-inflammatory activity in multiple preclinical models, but similar concerns over thrombocytopenia have stifled development of non-selective BET inhibitors. By sharing our selective BETi program success, we hope to motivate others to pursue epigenetic regulators outside of oncology. https://lnkd.in/etxRHCQy Save $150 with Discount code SPK150. #drugdiscoverychemistry

Presentation at PODD2024 Just finished my presentation at the Partnership Opportunities in Drug Delivery Meeting in Boston titled "Dramatic Oncolytic Virus Transduction Through Targeted and Protected Intravenous Administration." Vesselon develops drug co-formulations using an FDA-approved, biophysically activated lipid microsphere. These co-formulations safely make targeted tissues more receptive to therapeutic drugs, producing unprecedented levels of efficacy. Our third-generation oncolytic adenovirus has shown to produce far greater CD8+ infiltrates as well as tumor necrosis with our IV microsphere delivery system than intratumoral injections in a dual-flank triple negative breast cancer model.

🌟 Thrilling News! 🌟 Signet Therapeutics Inc., a portfolio company of BOCG, has received FDA IND approval for its groundbreaking targeted therapy for diffuse gastric cancer, moving into Phase I clinical trials. This therapy is the world's first to integrate organoid disease models with AI, developed in collaboration with XtalPi, showcasing rapid and efficient drug development. Beyond gastric cancer, this therapy shows promise in treating ovarian, triple-negative breast, and pancreatic cancers. BOCG is proud to support Signet Therapeutics' mission to bring effective therapies to patients worldwide. Read more here: https://lnkd.in/gGqr2YuG #BOCGPortfolio #BOCGFamily #Biotech #FDAApproval #ClinicalTrials #TargetedTherapy #BOCG #SignetTherapeutics #AI #Organoids #CancerResearch #Investment

🚀📑 💊 New Review Published! 💊📑🚀 I’m excited to share our latest review on lactate dehydrogenase (LDH) inhibitors patents from the past decade, published in Expert Opinion on Therapeutic Patents by Taylor & Francis Group! LDH inhibitors are crucial in targeting cancer metabolism, and this review highlights the most promising advancements. Our analysis provides a helpful roadmap for developing more potent and effective inhibitors that could revolutionize cancer treatment. Don’t miss it! Check out the full review here: https://lnkd.in/eANvQVFG #Innovation #LDHInhibitors #CancerResearch #DrugDevelopment #Patents

We invite you to visit our poster on the collaborative study with Nomocan Pharmaceuticals at the AACR 2024 in San Diego. Learn about the advantages of MDOTS (Mouse-Derived Organotypic Tumor Spheroids) and PDOTS ( Patient-Derived Organotypic Tumor Spheroids ) in advancing drug development. Our study highlights their roles in demonstrating drug efficacy and mechanism of action (MoA). The poster will be on April 8 from 1:30 AM to 5:00 PM. Michael Perricone will be available at the conference venue to connect with attendees interested in learning more about our platform. Advanced ex vivo platform for drug response analysis: Evaluating the potent effects of NMC-521 mAb on mouse-and patient-derived organotypic tumor spheroids #AACR #AACR2024 #PDOTS #MDOTS #geneexpression #Immunecontexture #solidtumors #oncology #cancer #tumormicroenvironment #spheroids #NSCLC

Domain Therapeutics, one of #RHUCONDOR partner will be presenting the groundbreaking insights on DT-9045, their first-in-class Negative Allosteric Modulator of PAR2, during the AACR annual meeting 2024. 🗓 7 April 2024 - from 1:30 PM – 5:00 PM PST 📍 Poster section 27 – PO.ET09.05 – Novel Antitumor Agents 2 👉 DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and #immunotherapy in #oncology models. Don't miss the chance to meet the Domain Therapeutics / RHU CONDOR members Thibaut Brugat, Nathalie Lenne, Stephan Schann and Marjorie Sidhoum and discuss with them about the PAR2 program, one of deliverables of CONDOR. #drugdevelopment #precisionmedecine #cancerresearch

𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 𝐓𝐫𝐞𝐨𝐬 𝐁𝐢𝐨 𝐭𝐨 𝐔𝐧𝐯𝐞𝐢𝐥 𝐍𝐞𝐰 𝐃𝐚𝐭𝐚 𝐨𝐧 𝐂𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐭 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒. Treos Bio, a biotech company specializing in precision peptide immunotherapies, will present phase 2 trial results of their PolyPEPI1018 product in combination with Roche's atezolizumab for treating microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting. This therapy aims to transform non-responsive 'cold' tumors into treatable 'hot' tumors, marking a significant advancement in the treatment of this prevalent cancer form, which currently sees limited benefit from existing immunotherapies. Stay tuned to our LinkedIn page for more updates and news. #peptides #biotech #ClinicalTrials #CancerResearch If you want to read the full news, check the link in comment.

New Treatment Approach in EGFR Exon 20+ NSCLC #Amivantamab. On March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. There are many more oral kinase inhibitors in pipeline. The treatment landscape for Exon 20 NSCLC is changing rapidly...#nsclc #lungcancer

We are excited to present an exclusive video interview with Shriya Joshi, Ph.D., a Scientist in Small Molecule Drug Discovery at Bristol Myers Squibb! As part of the 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference, Shriya will be shedding light on a critical yet often overlooked topic: Polyploid Giant Cancer Cells: The Senescent Actuators and Evil Root of Cancer Recurrence. In this interview, Shriya shares her journey and offers a sneak peek into her research, which focuses on the role of these unique cancer cells in disease recurrence. Her work is pushing the boundaries of our understanding and could pave the way for new therapeutic strategies. Tune in to get inspired by her passion and insights, and join us at the conference on June 20-21, 2024, at the Hilton Boston Logan Airport. Let's delve into the complexities of cancer biology together! #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets #immunooncologyconference2024 #bostonconference2024

Today, February 26, the ESMO Targeted Anticancer Therapies Congress 2024 starts in Paris, France! Take a look at the future of anticancer therapies, with a focus on new targets and agents in early development. If you are onsite, visit our sponsor BeiGene at booth no. 2 to learn about and discuss their innovative approaches. #ESMOTAT24 #clinicalresearch #oncology